Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

89Zr

  • Evaluation of Candidate Theranostics for <sup>227</sup>Th/<sup>89</sup>Zr Paired Radioimmunotherapy of Lymphoma
    Open Access
    Evaluation of Candidate Theranostics for 227Th/89Zr Paired Radioimmunotherapy of Lymphoma
    Diane S. Abou, Mark Longtine, Amanda Fears, Nadia Benabdallah, Ryan Unnerstall, Hannah Johnston, Kyuhwan Shim, Abbie Hasson, Hanwen Zhang, David Ulmert, Floriane Mangin, Serife Ozen, Laurent Raibaut, Stéphane Brandès, Michel Meyer, Jean-Claude Chambron, David S. Tatum, Darren Magda, Richard L. Wahl and Daniel L.J. Thorek
    Journal of Nuclear Medicine July 1, 2023, 64 (7) 1062-1068; DOI: https://doi.org/10.2967/jnumed.122.264979
  • Preclinical Evaluation of <sup>89</sup>Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis
    Open Access
    Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis
    Olli Moisio, Jenni Virta, Emrah Yatkin, Heidi Liljenbäck, Senthil Palani, Riikka Viitanen, Maxwell W.G. Miner, Vesa Oikonen, Tuula Tolvanen, Danielle J. Vugts, Pekka Taimen, Xiang-Guo Li, Maija Hollmén, Sirpa Jalkanen and Anne Roivainen
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 555-560; DOI: https://doi.org/10.2967/jnumed.122.264725
  • <sup>89</sup>Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted <sup>227</sup>Th-Conjugate Therapy in Mice
    You have access
    89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice
    Linda N. Broer, Daan G. Knapen, Frans V. Suurs, Ingrid Moen, Danique Giesen, Stijn J.H. Waaijer, Baard Indrevoll, Christine Ellingsen, Alexander Kristian, Alan S. Cuthbertson, Derk-Jan A. de Groot, Patricia E. Cole, Elisabeth G.E. de Vries, Urs B. Hagemann and Marjolijn N. Lub-de Hooge
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1715-1721; DOI: https://doi.org/10.2967/jnumed.121.263079
  • Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
    You have access
    Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
    Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776
  • 
<sup>89</sup>Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    You have access
    89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho and Kyung-Han Lee
    Journal of Nuclear Medicine May 10, 2021, 62 (5) 656-664; DOI: https://doi.org/10.2967/jnumed.120.250720
  • You have access
    Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44
    Philipp Diebolder, Cedric Mpoy, Jalen Scott, Truc T. Huynh, Ryan Fields, Dirk Spitzer, Nilantha Bandara and Buck E. Rogers
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 137-143; DOI: https://doi.org/10.2967/jnumed.120.249557
  • You have access
    Light-Induced Radiosynthesis of 89Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor
    Simon Klingler, Rachael Fay and Jason P. Holland
    Journal of Nuclear Medicine July 1, 2020, 61 (7) 1072-1078; DOI: https://doi.org/10.2967/jnumed.119.237180
  • You have access
    89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
    Yvonne W.S. Jauw, Joseph A. O’Donoghue, Josée M. Zijlstra, Otto S. Hoekstra, C. Willemien Menke-van der Houven van Oordt, Franck Morschhauser, Jorge A. Carrasquillo, Sonja Zweegman, Neeta Pandit-Taskar, Adriaan A. Lammertsma, Guus. A.M.S. van Dongen, Ronald Boellaard, Wolfgang A. Weber and Marc C. Huisman
    Journal of Nuclear Medicine December 1, 2019, 60 (12) 1825-1832; DOI: https://doi.org/10.2967/jnumed.118.224568
  • You have access
    Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
    Jorge A. Carrasquillo, Bernard M. Fine, Neeta Pandit-Taskar, Steven M. Larson, Stephen E. Fleming, Josef J. Fox, Sarah M. Cheal, Joseph A. O’Donoghue, Shutian Ruan, Govind Ragupathi, Serge K. Lyashchenko, John L. Humm, Howard I. Scher, Mithat Gönen, Simon P. Williams, Daniel C. Danila and Michael J. Morris
    Journal of Nuclear Medicine November 1, 2019, 60 (11) 1517-1523; DOI: https://doi.org/10.2967/jnumed.118.222844
  • You have access
    Fully Automated 89Zr Labeling and Purification of Antibodies
    Alex J. Poot, Kevin W.A. Adamzek, Albert D. Windhorst, Maria J.W.D. Vosjan, Saskia Kropf, Hans-Jurgen Wester, Guus A.M.S. van Dongen and Danielle J. Vugts
    Journal of Nuclear Medicine May 1, 2019, 60 (5) 691-695; DOI: https://doi.org/10.2967/jnumed.118.217158

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire